Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 601 to 610 of 2733 total matches.
In Brief: Plan B One-Step OTC
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013 (Issue 1419)
contraception as two 0.75-mg tablets
taken 12 hours apart (generic formulations of Plan B) and
as a single 1 ...
The progestin levonorgestrel is available over the counter for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B) and as a single 1.5-mg tablet taken once (Plan B One-Step, and generics). A third emergency contraceptive, ulipristal (Ella – Watson), is available with a prescription.1 It appears that, pursuant to a court order, Plan B One-Step (but not the generic products), which was previously available over the counter from a pharmacist only for women 17 years and older, will now be available directly from pharmacy shelves with no age...
In Brief: Liposomal Irinotecan (Onivyde) for Pancreatic Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
to irinotecan and improves the cellular uptake
and cytotoxic effect of the drug.1
FDA approval of liposomal ...
A liposomal formulation of irinotecan (Onivyde – Merrimack) has been approved by the FDA for use in combination with fluorouracil and leucovorin for treatment of metastatic pancreatic cancer that has progressed after gemcitabine-based therapy. A non-liposomal formulation of irinotecan (Camptosar, and generics) has been available in the US for many years. The liposomal carrier prolongs exposure to irinotecan and improves the cellular uptake and cytotoxic effect of the drug.1FDA approval of liposomal irinotecan was based on the results of an open-label trial (NAPOLI-1) in 417 patients with...
In Brief: Trifluridine/Tipiracil (Lonsurf) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
with trifluridine/tipiracil compared to
placebo (7.1 months vs 5.3 months). Median progressionfree
survival ...
The FDA has approved Lonsurf (Taiho Oncology), a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil, for oral treatment of metastatic colorectal cancer. Trifluridine is incorporated into DNA, interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil inhibits the metabolism of trifluridine. The combination is only approved for use in patients who were previously treated with a fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF biological such as bevacizumab, and, if the tumor...
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
Glycopyrrolate (Dartisla ODT) for Peptic Ulcer Symptoms
1. KJ Ivey. Anticholinergics: do they work ...
The FDA has approved adjunctive treatment with
Dartisla ODT (Edenbridge), a new orally disintegrating
tablet (ODT) formulation of the anticholinergic drug
glycopyrrolate, to reduce symptoms of a peptic ulcer.
Glycopyrrolate oral tablets (Robinul, Robinul Forte,
and generics) were approved for the same indication
in 1961.
In Brief: Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
4, 2024
The FDA is requiring a boxed warning in the label
of denosumab (Prolia – Amgen)1 ...
The FDA is requiring a boxed warning in the label
of denosumab (Prolia – Amgen), a monoclonal
antibody that inhibits osteoclasts, about an
increased risk of severe hypocalcemia in patients
with advanced chronic kidney disease (CKD;
eGFR <30 mL/min/1.73 m2), particularly those on
dialysis. FDA-approved indications for Prolia are
listed in Table 1.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):40 doi:10.58347/tml.2024.1697c | Show Introduction Hide Introduction
Topical Treatment for Bacterial Vaginosis
The Medical Letter on Drugs and Therapeutics • Nov 27, 1992 (Issue 884)
vaginosis
treated with intravaginal 0.1%, 1%, or 2% clindamycin were cured four to seven days after ...
A 0.75% vaginal gel formulation of metronidazole (MetroGel-Vaginal - Curatek) and a 2% vaginal cream formulation of clindamycin phosphate (Cleocin - Upjohn) were recently approved by the US Food and Drug Administration for treatment of bacterial vaginosis. Seven days' treatment with oral metronidazole, 500 mg b.i.d., has been the usual treatment for this condition, with oral clindamycin, 300 mg b.i.d., as an alternative (JL Thomason et al, Am J Obstet Gynecol, 165:1210, 1991).
Ibutilide
The Medical Letter on Drugs and Therapeutics • Apr 12, 1996 (Issue 972)
placebo, in 37 (43%) of 86 receiving one or,
if necessary, two 1-mg infusions of ibutilide, and in 41 (44 ...
Ibutilide fumarate (Corvert - Pharmacia & Upjohn), a new antiarrhythmic drug for intravenous use, has been approved by the US Food and Drug Administration for acute termination of atrial fibrillation or flutter of recent onset.
Azelaic Acid - A New Topical Drug for Acne
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996 (Issue 976)
corneum (H
Gollnick, J Dermatol Treat, 4 suppl 1:S3, 1993). Applied to the skin, about 4% of the drug ...
Azelaic acid, a naturally occurring heptanedicarboxylic acid, has been marketed in the USA as a 20% cream (Azelex - Allergan) for treatment of acne. The drug has been available in Europe for several years.
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
cisplatin (Platinol) found that a single dose of 1.8 mg/kg of dolasetron IV was completely effective ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Aromatase Inhibitors for Adjuvant Treatment of Postmenopausal Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011 (Issue 1366)
(AI) have become the preferred first-line hormonal
treatment over tamoxifen for such patients.1 ...
Adjuvant hormone therapy with anti-estrogen drugs has
been shown to reduce disease recurrence and mortality
in postmenopausal women with estrogen receptor (ER)-positive breast cancer. In recent years, aromatase
inhibitors (AI) have become the preferred first-line hormonal
treatment over tamoxifen for such patients.1,2
